Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein biomarker analysis across a range of multiplex levels in biofluid samples. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method reducing background signal and increasing sensitivity and dynamic range compared with standard approaches. The NULISA Platform allows for a fully automated workflow with the ARGO™ HT System enabling less than 30 minutes hands-on time from sample to data.
BrainXell provides high-purity, iPSC-derived human neurons and glia for research and development with a focus on drug discovery. Utilizing proprietary technology, we generate high-purity, subtype-specific neurons that mature rapidly and are quickly and easily ready for a variety of assays. Multiple neuron subtypes relevant to a range of disorders are available. Additionally, each neuron subtype can be made in custom batches from 50 million to 10 billion neurons from unique iPSC lines. We are dedicated to delivering the highest quality products for off-the-shelf neurons and custom service projects.
At Cellectricon, we create new avenues for neuroscience drug discovery. Our mission is
to create groundbreaking concepts that will advance the neuroscience research field.
From early concept evaluation to transformative drug discovery campaigns, we solve your
scientific challenges through innovative approaches for in vitro research.
Obtain new insights into disease biology
Accelerate the R&D process and reduce time-to-decision making
Identify targets and lead compounds with potential to produce first-in-class medicines
Our unique discovery platform combines drug discovery expertise and disease area
knowledge with cutting-edge technologies. With the platform, we are creating complex
disease models and assays for functional and morphological screening.
bit.bio is a synthetic biology company focused on human cells that is advancing medicine and enabling curative treatments. bit.bio's opti-ox™ precision cell programming technology enables conversion of induced pluripotent stem cells (iPSCs) into any desired human cell type in a single step, at industrial scale, while maintaining exceptional purity and consistency.
The ioCells™ research cell product portfolio is opening up new possibilities for studying human biology and developing new medicines in research and drug discovery.
Atuka provides contract research and consultancy services for the biopharmaceutical industry with world-leading expertise in Parkinson’s disease and related neurological conditions. We provide cutting-edge, rodent and non-human primate models (toxin and molecular pathology-driven) to evaluate efficacy and target engagement over a comprehensive range of symptomatic, motor (e.g. parkinsonism and dyskinesia), non-motor (e.g. cognition and impulse control) and disease-modification assays. Atuka also offers biodistribution (e.g. AAVs, ASOs) and non-GLP safety assessments in non-human primates, DMPK and in-vivo imaging services to aid development of novel therapeutics.